To develop cell culture and small animal models of Nipah virus replication and pathogenesis in a biosafety level (BSL) 4 lab.

To investigate other novel interventions, such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality substantially in this population at risk for severe malaria and death.

To support the characterization of non-rotavirus viral diarrheal pathogens to inform the body of work that contributes to optimize the efficacy of rotavirus vaccines.